Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Financing translation: Analysis of the NCATS rare-diseases portfolio

25 Feb 2015

Abstract excerpt

The portfolio of the National Center for Advancing Translational Sciences (NCATS) rare-diseases therapeutic development program comprises 28 research projects initiated at the preclinical stage. Historical data reveal substantially lower costs and higher success rates but longer preclinical timelines for the NCATS projects relative to the industry averages for early-stage translational medical research and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biotechnology and Related Fields
Share to Health Systems, Economic Evaluations, Quality of Life

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 25717096
DOI: 10.1126/scitranslmed.aaa2360

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Financing translation: Analysis of the NCATS rare-diseases portfolioPMID 25717096Read ↗

Non-commercial pharmaceutical R&D: what do neglected diseases suggest about costs and efficiency?Semantic proximity Read ↗

Rare Disease Curative Care Expenditure- Financing Scheme-Health Provider- Beneficiary Group Analysis — An Empirical Study in Sichuan Province, ChinaSemantic proximity Read ↗

The Amortization of Funding Gene Therapies: Making the “Intangibles” Tangible for PatientsSemantic proximity Read ↗

The Net Financial Benefits of Single Vendor Integrated CDMO and CRO Drug Development ServicesSemantic proximity Read ↗

Cell and gene therapy investment: evolution and future outlook on investor perspectivesSemantic proximity Read ↗

Estimating the Financial Impact of Gene Therapy*Semantic proximity Read ↗

The Allocation of US$ 105 Billion in Global Funding for Infectious Disease Research between 2000 and 2017: An Analysis of Investments from Funders in the G20 CountriesSemantic proximity Read ↗

Quantifying the Dual Value and Governance Risks of Early Access Programs in Oncology: A Single-Centre Analysis and National Policy FrameworkSemantic proximity Read ↗

“A Process-Based Approach to Conflicts of Interest”Semantic proximity Read ↗

Pharmaceutical Drug Lifecycle: A Comprehensive Scientific Review of Research and Development Phases, Attrition Rates, and Global DisparitiesSemantic proximity Read ↗

Clinical Advancement ForecastingSemantic proximity Read ↗

Measuring the Impact of Global R&D Investment in Product Development Partnerships (PDPs): A Case Study on Return on Investment in Antimalarial Drug DevelopmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.